Sökning: onr:"swepub:oai:gup.ub.gu.se/333242" > Are JAKis more effe...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 07225naa a2200733 4500 | |
001 | oai:gup.ub.gu.se/333242 | |
003 | SwePub | |
008 | 240910s2023 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:154665333 | |
009 | oai:DiVA.org:uu-521845 | |
009 | oai:lup.lub.lu.se:1bef2d41-0240-49ca-b2d8-322ddf8a5416 | |
024 | 7 | a https://gup.ub.gu.se/publication/3332422 URI |
024 | 7 | a https://doi.org/10.1136/rmdopen-2023-0036482 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1546653332 URI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5218452 URI |
024 | 7 | a https://lup.lub.lu.se/record/1bef2d41-0240-49ca-b2d8-322ddf8a54162 URI |
040 | a (SwePub)gud (SwePub)kid (SwePub)uud (SwePub)lu | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Bower, Hannahu Karolinska Institute,Karolinska Institutet,Karolinska Inst, Dept Med Solna, Clin Epidemiol Div, Stockholm, Sweden.4 aut |
245 | 1 0 | a Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden. |
264 | 1 | b BMJ Publishing Group Ltd,c 2023 |
520 | a To investigate whether the relative effectiveness of janus kinase inhibitors (JAKis) versus tumour necrosis factor inhibitors (TNFi) or other biological disease-modifying antirheumatic drugs in rheumatoid arthritis differ by the presence or absence of risk factors for cardiovascular (CV) disease, age, sex and smoking.Through Swedish registers, we identified 13493 individuals with 3166 JAKi, 5575 non-TNFi and 11 286 TNFi treatment initiations 2016-2022. All lines of therapy were included, with the majority in second line or higher. Treatment response was defined as the proportion reaching European Alliance of Associations for Rheumatology (EULAR) good response and Clinical Disease Activity Index (CDAI) remission, respectively, within 6 months. Crude percentage point differences in these proportions (JAKis, and non-TNFis, vs TNFis) overall and by risk factors were observed, and adjusted for confounders using linear regression models. Predicted probabilities of response and remission were estimated from adjusted Poisson models, and presented across CV risk and age.Overall, adjusted percentage point differences indicated higher response (+5.0%, 95% CI 2.2% to 7.9%) and remission (+5.8%, 95% CI 3.2% to 8.5%) with JAKis versus TNFis. The adjusted percentage point differences for response in those above 65, at elevated CV risk, and smokers were +5.9% (95% CI 2.7% to 9.0%), +8.3% (95% CI 5.3% to 11.4%) and +6.0% (95% CI 3.3% to 8.7%), respectively. The corresponding estimates for remission were +8.0% (95% CI 5.3% to 10.8%), +5.6% (95% CI 3.0% to 8.2%) and +7.6% (95% CI 5.5% to 9.7%).As used in clinical practice, response and remission at 6 months with JAKis are higher than with TNFi. Among patients with risk factors of concern, effectiveness is similar or numerically further increased. For individualised benefit-to-risk ratios to guide treatment choice, safety and effectiveness in specific patient segments should be considered. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reumatologi och inflammation0 (SwePub)302102 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Rheumatology and Autoimmunity0 (SwePub)302102 hsv//eng |
653 | a Humans | |
653 | a Aged | |
653 | a Sweden | |
653 | a epidemiology | |
653 | a Janus Kinase Inhibitors | |
653 | a Smokers | |
653 | a Cardiovascular Diseases | |
653 | a epidemiology | |
653 | a etiology | |
653 | a Risk Factors | |
653 | a Tumor Necrosis Factor-alpha | |
653 | a Tumor Necrosis Factor Inhibitors | |
653 | a Heart Disease Risk Factors | |
653 | a Arthritis | |
653 | a Arthritis, Rheumatoid | |
653 | a Biological Therapy | |
653 | a Epidemiology | |
700 | 1 | a Frisell, Thomasu Karolinska Institute,Karolinska Institutet,Karolinska Inst, Dept Med Solna, Clin Epidemiol Div, Stockholm, Sweden.4 aut |
700 | 1 | a di Giuseppe, Danielau Karolinska Institute,Karolinska Institutet,Karolinska Inst, Dept Med Solna, Clin Epidemiol Div, Stockholm, Sweden.4 aut |
700 | 1 | a Delcoigne, Benedicteu Karolinska Institute,Karolinska Institutet,Karolinska Inst, Dept Med Solna, Clin Epidemiol Div, Stockholm, Sweden.4 aut |
700 | 1 | a Lindström, Ulfu Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research,Univ Gothenburg, Inst Med, Sahlgrenska Acad, Dept Rheumatol & Inflammat Res, Gothenburg, Sweden.,Sahlgrenska Academy4 aut0 (Swepub:lu)bioo-uli |
700 | 1 | a Turesson, Carlu Lund University,Lunds universitet,Reumatologi,Forskargrupper vid Lunds universitet,Rheumatology,Lund University Research Groups4 aut0 (Swepub:lu)med-ctn |
700 | 1 | a Chatzidionysiou, Katerinau Karolinska Institutet,Karolinska Univ Hosp, Rheumatol Theme Inflammat & Ageing, Stockholm, Sweden.,Karolinska University Hospital4 aut |
700 | 1 | a Lindqvist, Elisabetu Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lund Arthritis Research Group (LARG),Forskargrupper vid Lunds universitet,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups4 aut0 (Swepub:lu)reum-eli |
700 | 1 | a Knight, Annu Uppsala University,Uppsala universitet,Reumatologi4 aut0 (Swepub:uu)ankni172 |
700 | 1 | a Forsblad d'Elia, Helena,d 1961u Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine,Institute of Medicine, Department of Rheumatology and Inflammation Research,Univ Gothenburg, Inst Med, Sahlgrenska Acad, Dept Rheumatol & Inflammat Res, Gothenburg, Sweden.,Sahlgrenska Academy4 aut0 (Swepub:gu)xforhe |
700 | 1 | a Askling, Johanu Karolinska Institute,Karolinska Institutet,Karolinska Inst, Dept Med Solna, Clin Epidemiol Div, Stockholm, Sweden.;Karolinska Univ Hosp, Rheumatol Theme Inflammat & Ageing, Stockholm, Sweden.,Karolinska University Hospital4 aut |
710 | 2 | a Karolinska Institutetb Karolinska Inst, Dept Med Solna, Clin Epidemiol Div, Stockholm, Sweden.4 org |
773 | 0 | t RMD opend : BMJ Publishing Group Ltdg 9:4q 9:4x 2056-5933 |
856 | 4 | u https://doi.org/10.1136/rmdopen-2023-003648y Fulltext |
856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:1832318/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 | u http://dx.doi.org/10.1136/rmdopen-2023-003648x freey FULLTEXT |
856 | 4 8 | u https://gup.ub.gu.se/publication/333242 |
856 | 4 8 | u https://doi.org/10.1136/rmdopen-2023-003648 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:154665333 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-521845 |
856 | 4 8 | u https://lup.lub.lu.se/record/1bef2d41-0240-49ca-b2d8-322ddf8a5416 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy